Sun Pharma tanks 4% on reports USFDA issued notice on Halol plant

The stock has shed 7% in the last 4 days, including today

Phillips-Medisize's medical & clean room moulding facility
Phillips-Medisize's medical & clean room moulding facility
SI Reporter New Delhi
Last Updated : Dec 07 2016 | 1:09 PM IST
Extending losses for the fourth straight session, shares of Sun Pharma on Wednesday slipped over 4% on news report that US Food and Drug Administration has issued notice to the pharma major after having inspected its Halol unit in Gujarat.

Reacting to the development, the stock of the company fell as much as 4.50% on the BSE, and was the worst performing stock on Sensex. The stock has shed 7% in the last 4 days, including today. 

By afternoon, a total of 42 crore shares changed hands on the counter on BSE, compared with a two-week daily average of 6.79 lakh shares.

Meanwhile, the Exchange sought clarification from Sun Pharmaceutical with reference to ET NOW quoting "USFDA informs that Halol issued 14-page Form 483 post inspection".
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 07 2016 | 1:01 PM IST

Next Story